Novo Nordisk increased operating profit in Danish kroner by 73% in the first quarter of 2015 to DKK 13.9 billion
(Thomson Reuters ONE) -
17% local currency operating profit growth adjusted for the NNIT divestment
Sales increased by 24% in Danish kroner and by 9% in local currencies to DKK
25.2 billion.
* Sales of Victoza(®) increased by 36% (18% in local currencies).
* Sales of Levemir(®) increased by 31% (13% in local currencies).
* Sales in North America increased by 34% (11% in local currencies).
* Sales in International Operations increased by 22% (12% in local
currencies).
* Sales in Region China increased by 31% (11% in local currencies).
Gross margin improved by 1.6 percentage points in Danish kroner to 84.6% driven
by a positive currency impact.
Operating profit increased by 73% in Danish kroner and by 47% in local
currencies to DKK 13.9 billion. Adjusted for the DKK 2.4 billion non-recurring
income related to the partial divestment of NNIT, operating profit in local
currencies increased by 17%.
Net profit increased by 53% to DKK 9.9 billion. Diluted earnings per share
increased by 56% to DKK 3.79. Adjusted for the partial divestment of NNIT, net
profit and diluted earnings per share increased by 22% and 24% respectively.
In March, Novo Nordisk announced the decision to submit the prespecified interim
analysis of DEVOTE, the cardiovascular outcomes trial for Tresiba(®), to the US
FDA. The submission was accepted for review by the FDA in April.
Novo Nordisk reorganises its Executive Management, elevating the leaders of the
commercial activities in the US, Europe and International Operations and of
Product Supply to Executive Management. Kåre Schultz, president and COO, leaves
Novo Nordisk.
For 2015, sales growth measured in local currencies is now expected to be 7-9%,
whereas operating profit growth measured in local currencies is expected to be
around 17%.
Lars Rebien Sørensen, CEO: "We are very pleased with the results during the
first quarter of 2015. Victoza(®) and Levemir(®) continue to drive sales growth,
and we have successfully passed several critical milestones for our portfolio of
late-stage diabetes care projects." Commenting on the changes in Executive
Management, he adds: "Kåre Schultz has during his 26 years with us played a key
role in making Novo Nordisk a successful global company. I wish him all the best
in his future endeavours."
Further information
Media:
Katrine Sperling +45 30796718 krsp(at)novonordisk.com
Ken Inchausti (US) +1 609 514 8316 kiau(at)novonordisk.com
Investors:
Kasper Roseeuw Poulsen +45 3079 4303 krop(at)novonordisk.com
Daniel Bohsen +45 3079 6376 dabo(at)novonordisk.com
Melanie Raouzeos +45 3075 3479 mrz(at)novonordisk.com
Frank Daniel Mersebach (US) +1 609 235 8567 fdni(at)novonordisk.com
Company announcement No 31 / 2015
Company announcement No 31 / 2015:
http://hugin.info/2013/R/1916948/685685.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Novo Nordisk A/S via GlobeNewswire
[HUG#1916948]
Unternehmensinformation / Kurzprofil:
Datum: 30.04.2015 - 07:31 Uhr
Sprache: Deutsch
News-ID 389674
Anzahl Zeichen: 3811
contact information:
Town:
Bagsvaerd
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 135 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Novo Nordisk increased operating profit in Danish kroner by 73% in the first quarter of 2015 to DKK 13.9 billion"
steht unter der journalistisch-redaktionellen Verantwortung von
Novo Nordisk A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
